Comprehensive Blood & Cancer Center

InstitutionResearch output, impact & collaborations

Comprehensive Blood & Cancer Center is a research organisation in Bakersfield, US. OpenAlex records 1,019 works and 227,877 citations for it. 222 researchers list it as their most recent affiliation.

1,019

Works

227,877

Citations

222

Researchers

100

Avg h-index

IDs:ROR OpenAlex

How has Comprehensive Blood & Cancer Center's publication output changed over time?

ScholarIQpublication output · 2005–2021

Output grew0% over the shown period — from 1 works in 2005 to 1 in 2021.

200520082009201320152016201720182021

What are the most-cited papers on Comprehensive Blood & Cancer Center?

ScholarIQmost cited works

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara

The Lancet. 20164,795 CitationsOPEN ACCESS

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Giorgio V. Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, U. Gatzemeier, Raghunadharao Digumarti, Mauro Zukin, Jin S. Lee, Anders Mellemgaard, Keunchil Park, Shehkar Patil, Janusz Rolski, Tuncay Göksel, Filippo de Marinis, Lorinda Simms, Katherine P. Sugarman, David R. Gandara

Journal of Clinical Oncology. 20083,230 Citations

Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

Timothy Winton, Robert B. Livingston, David C. Johnson, James R. Rigas, Michael Johnston, Charles Butts, Yvon Cormier, Glenwood Goss, Richard Inculet, Eric Vallières, Willard A. Fry, Drew Bethune, Joseph Ayoub, Keyue Ding, Lesley Seymour, Barbara Graham, Ming‐Sound Tsao, David R. Gandara, Kenneth A. Kesler, Todd L. Demmy, Frances A. Shepherd

New England Journal of Medicine. 20051,834 CitationsOPEN ACCESS

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

Kathy S. Albain, Ruth Swann, Valerie W. Rusch, Andrew T. Turrisi, Frances A. Shepherd, Colum J Smith, Yuhchyau Chen, Robert B. Livingston, Richard H. Feins, David R. Gandara, Willard A. Fry, Gail Darling, David H. Johnson, Mark R. Green, Robert C. Miller, Joanne Ley, W. Sause, James D. Cox

The Lancet. 20091,479 Citations

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi, Julien Mazières, David Planchard, Thomas E. Stinchcombe, Grace K. Dy, Scott Antonia, Leora Horn, H. Léna, Elisa Minenza, B. Mennecier, Gregory A. Otterson, Luis T. Campos, David R. Gandara, Benjamin Levy, Suresh Nair, Gérard Zalcman, Jürgen Wolf, Pierre‐Jean Souquet, Editta Baldini, Federico Cappuzzo, C. Chouaïd, Afshin Dowlati, Rachel E. Sanborn, Ariel López-Chávez, Christian Grohé, Rudolf M. Huber, Christopher Harbison, Christine Baudelet, Brian Lestini, Suresh S. Ramalingam

The Lancet Oncology. 20151,434 Citations